alexa The σ1 Receptor As Target For Novel Drugs
ISSN: 2161-0444

Medicinal chemistry
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

3rd International Conference on Medicinal Chemistry & Computer Aided Drug Designing
December 08-10, 2014 DoubleTree by Hilton Hotel San Francisco Airport, USA

Bernhard W?nsch
ScientificTracks Abstracts: Med Chem
DOI: 10.4172/2161-0444.S1.011
Abstract
Originally the opioid receptor was subclassified into three subtypes, which were termed after their prototypical ligands μ (morphine), K (ketocyclazocine) and σ receptors (SKF-10, 047). However, this hypothesis was disproved, since the pharmacological effects of typical σ receptor drugs were not reversed by the opioid receptor antagonists naloxone and naltrexone. Finally, σ receptors were recognized as specific, non-opioid, non-PCP, but haloperidol-sensitive binding sites consisting of σ1 and σ2 subtypes. The two σ receptor subtypes can be differentiated by molecular weight, tissue distribution, and ligand binding profile. It has been shown that the σ1 receptor plays an important role in several socially relevant human diseases including schizophrenia, depression, Alzheimer?s disease, and drug/alcohol addiction. Antagonists at the σ1 receptor potentiate the pain-relieving effects of opioid analgesics and, moreover, can be used for the treatment of neurogenic pain. Due to their overexpression in several human tumor cell lines, σ1 and σ2 receptors are interesting targets for tumor therapy and diagnosis. In the lecture the interactions of ligands with the binding site of the σ1 receptor are analyzed. The design and synthesis of novel σ1 receptor ligands is presented. Spirocyclic piperidines and bridged piperazines represent very promising σ1 receptor ligands for further pharmacological evaluation. The development of a PET tracer for the imaging of σ1 receptors in the central nervous system is shown.
Biography
Bernhard W?nsch has completed his PhD in 1987 from the University of Munich. After postdoctoral studies at the University of Berlin, he finished his habilitation in 1993. Then he moved to the University of Freiburg and finally to the University of M?nster, where he is director of the Institute of Pharmaceutical and Medicinal Chemistry. He has been the dean of the faculty from 2005-2006. He is member of the collaborative research center 656 (Molecular Cardiovascular Imaging) and the Cluster of Excellence CiM (Cells in Motion). He has published more than 200 papers in reputed journals.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords